TNFRSF17 and Miyoshi myopathy: Additionally, another investigation revealed that reduced serum ALB concentrations function as predictive biomarkers for both the toxicity profile and clinical outcomes in MM patients undergoing anti-BCMA CAR-T cell therapy (17).